A pilot study of temsirolimus and body composition

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 4, 2013, Pages 259-265

  Veasey Rodrigues, Heloisa ^a   Parsons, Henrique A ^a   Janku, Filip ^a   Naing, Aung ^a   Wheler, Jennifer J ^a   Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Body composition; Sarcopenia; Temsirolimus; Toxicity

Indexed keywords

TEMSIROLIMUS;

ADIPOSE TISSUE; ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANUS CANCER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; BODY WEIGHT; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; ENDOMETRIUM CANCER; FAT MASS; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOPENIA; SIDE EFFECT; SKELETAL MUSCLE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

EID: 84888038950     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0113-y     Document Type: Article

References (33)

1. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344: 783-92.
2. Verweij J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364: 1127-34.
3. Kwak EL et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363: 1693-703.
4. Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364: 2507-16.
5. Prado CM et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9: 629-35.
6. Murthy NS et al. Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med. 2009;55: 45-54.
7. Prado CM et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15: 2920-6.
8. Aslani A et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer. 2000;88: 796-803.
9. Prado CM et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13: 3264-8.
10. Dewys WD et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69: 491-7.
11. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26: 146-51.
12. Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-81.
13. Bodine SC et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3: 1014-9.
14. McCarthy JJ, Esser KA. Anabolic and catabolic pathways regulating skeletal muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13: 230-5.
15. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009;19: R1046-52.
16. Houde VP et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59: 1338-48.
17. Bhojani N et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53: 917-30.
18. Therasse P et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-16.
19. Trotti A et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13: 176-81.
20. Billewicz WZ, Kemsley WF, Thomson AM. Indices of adiposity. Br J Prev Soc Med. 1962;16: 183-8.
21. Mitsiopoulos N et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85: 115-22.
22. Shen W et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97: 2333-8.
23. Mourtzakis M et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33: 997-1006.
24. Yao JC et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 514-23.
25. Vogt PK. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med. 2001;7: 482-4.
26. Antoun S et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28: 1054-60.
27. Parsons HA et al. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012;7: e29330.
28. Tan BH et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15: 6973-9.
29. Antoun S et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21: 1594-8.
30. Chow WH et al. Obesity and risk of renal cell cancer. Cancer Epidemiol Biomark Prev. 1996;5: 17-21.
31. Steffens S et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist. 2011;16: 1565-71.
32. Tang PA, Heng DY, Choueiri TK. Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist. 2011;16: 1484-6.
33. Ladoire S et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16: 71-81.